Psychedelic Science Review
Filament Health Announces Third Quarter 2024 Financial Results And Operational Highlights
Innovative trial will use psilocybin to target relapse in opioid addiction
Filament Health Announces Issuance Of Common Shares To Negev Capital Investments Limited Pursuant To Advisory Agreement